These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 15837864)

  • 1. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
    Lebwohl M; Dinehart S; Whiting D; Lee PK; Tawfik N; Jorizzo J; Lee JH; Fox TL
    J Am Acad Dermatol; 2004 May; 50(5):714-21. PubMed ID: 15097955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology.
    Szeimies RM; Gerritsen MJ; Gupta G; Ortonne JP; Serresi S; Bichel J; Lee JH; Fox TL; Alomar A
    J Am Acad Dermatol; 2004 Oct; 51(4):547-55. PubMed ID: 15389189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.
    Alomar A; Bichel J; McRae S
    Br J Dermatol; 2007 Jul; 157(1):133-41. PubMed ID: 17501955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream.
    Lee PK; Harwell WB; Loven KH; Phillips TJ; Whiting DA; Andres KL; Lee JH
    Dermatol Surg; 2005 Jun; 31(6):659-64. PubMed ID: 15996416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses.
    Stockfleth E; Meyer T; Benninghoff B; Salasche S; Papadopoulos L; Ulrich C; Christophers E
    Arch Dermatol; 2002 Nov; 138(11):1498-502. PubMed ID: 12437457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head.
    Stockfleth E; Sterry W; Carey-Yard M; Bichel J
    Br J Dermatol; 2007 Dec; 157 Suppl 2():41-6. PubMed ID: 18067631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial.
    Ooi T; Barnetson RS; Zhuang L; McKane S; Lee JH; Slade HB; Halliday GM
    Br J Dermatol; 2006 Jan; 154(1):72-8. PubMed ID: 16403097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head.
    Rivers JK; Rosoph L; Provost N; Bissonnette R
    J Cutan Med Surg; 2008; 12(3):97-101. PubMed ID: 18544290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    Br J Dermatol; 2007 Dec; 157(6):1132-47. PubMed ID: 17944981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.
    Jorizzo J; Dinehart S; Matheson R; Moore JK; Ling M; Fox TL; McRae S; Fielder S; Lee JH
    J Am Acad Dermatol; 2007 Aug; 57(2):265-8. PubMed ID: 17512087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
    Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
    Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases.
    Stockfleth E; Meyer T; Benninghoff B; Christophers E
    Br J Dermatol; 2001 May; 144(5):1050-3. PubMed ID: 11359396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients.
    Ulrich C; Bichel J; Euvrard S; Guidi B; Proby CM; van de Kerkhof PC; Amerio P; Rønnevig J; Slade HB; Stockfleth E
    Br J Dermatol; 2007 Dec; 157 Suppl 2(Suppl 2):25-31. PubMed ID: 18067628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.